search
Back to results

Comparative Study of 99mTc-FAPI SPECT/CT and 68Ga-FAPI PET/CT

Primary Purpose

99mTc-FAPI-positive Gastrointestinal Tumor

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
99mTc-FAPI
Sponsored by
Xijing Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for 99mTc-FAPI-positive Gastrointestinal Tumor

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • patients with gastrointestinal tumors: diagnosed by pathological needle biopsy

Exclusion Criteria:

  • refuse or cannot endure surgery pregnant women

Sites / Locations

    Outcomes

    Primary Outcome Measures

    SUV of primary and metastases lesions
    The standardized uptake values (SUV) in deferent organs and lesions

    Secondary Outcome Measures

    Full Information

    First Posted
    June 26, 2022
    Last Updated
    July 4, 2022
    Sponsor
    Xijing Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05444686
    Brief Title
    Comparative Study of 99mTc-FAPI SPECT/CT and 68Ga-FAPI PET/CT
    Official Title
    Comparative Study of 99mTc-FAPI Quantitative SPECT/CT and 68Ga-FAPI PET/CT in Clinical Diagnosis and Staging of Gastrointestinal Tumors
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    July 1, 2022 (Anticipated)
    Primary Completion Date
    June 30, 2024 (Anticipated)
    Study Completion Date
    July 30, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Xijing Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to compare the similarities and differences of 99mTc-FAPI quantitative SPECT/CT and 68Ga-FAPI PET/CT in the diagnosis and staging of gastrointestinal tumors, and clinical diagnosis and economic value of 99mTc-FAPI quantitative SPECT/CT for the gastrointestinal tumors.
    Detailed Description
    5 healthy volunteers with whole body 99mTc-FAPI quantitative SPECT/CT scans at 1, 2, 4, 6 and 24 hours after tracer injection (mean dose, 20.0 ± 2.0 mCi) will be performed. During the imaging period, 1 mL blood samples will be obtained specifically at 1, 2, 4, 6 and 24 hours after the injection, for time-activity curve calculations. The estimated radiation doses will be calculated by using OLINDA/EXM software. Forty patients with confirmed or suspected gastrointestinal tumors, whole body 99mTc-FAPI quantitative SPECT/CT scans will be performed on the first day, and whole body 68Ga-FAPI PET/CT scans will be performed on the next day.According to the scans results of the two agents, with SUVmax and SUVmean as the analysis indicators, the number and uptake difference of primary tumor and metastatic lesions will be compared and analyzed.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    99mTc-FAPI-positive Gastrointestinal Tumor

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    45 (Anticipated)

    8. Arms, Groups, and Interventions

    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    99mTc-FAPI
    Intervention Description
    inject the tracer to subjects and perform SPECT/CT scans
    Primary Outcome Measure Information:
    Title
    SUV of primary and metastases lesions
    Description
    The standardized uptake values (SUV) in deferent organs and lesions
    Time Frame
    2 hours after injection

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: patients with gastrointestinal tumors: diagnosed by pathological needle biopsy Exclusion Criteria: refuse or cannot endure surgery pregnant women
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jing Wang, M.D, Ph.D
    Phone
    86-29-84775449
    Email
    wangjing@fmmu.edu.cn

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Comparative Study of 99mTc-FAPI SPECT/CT and 68Ga-FAPI PET/CT

    We'll reach out to this number within 24 hrs